A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

Experimental: Part A- Dose escalation of CM24 in combination with nivolumab
Drug: CM-24 and Nivolumab – Dose Escalation
Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors

Experimental: Part C- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine
Drug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine – Expansion
Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer

Experimental: Part C- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV – Expansion
Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer

Experimental: Part D- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine
Drug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine – Expansion
Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer

Experimental: Part D- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV – Expansion
Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer

Active Comparator: Part D- Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine
Drug: Nivolumab, Nab paclitaxel and Gemcitabine – Expansion
Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer

Active Comparator: Part D- Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV
Drug: Nivolumab and Nal-IRI/5-FU/LV – Expansion
Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 22, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments